JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Larimar Therapeutics (NASDAQ:LRMR) and maintained a $25 price target.
March 15, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities maintains a Market Outperform rating and a $25 price target on Larimar Therapeutics.
The reiteration of a Market Outperform rating and a maintained price target of $25 by a reputable analyst suggests a strong vote of confidence in Larimar Therapeutics' potential. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in LRMR's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100